X4 PHARMACEUTICALS INC. - COMMON STOCK

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 ديسمبر 2023 16:05:00 بحسب Nasdaq GlobeNewswire

X4 Pharmaceuticals to Participate in Upcoming November Investor Conferences

10 نوفمبر 2023 08:00:00 بحسب Nasdaq GlobeNewswire

X4 Pharmaceuticals Reports Third-Quarter 2023 Financial Results and Provides Corporate Updates

09 نوفمبر 2023 06:01:00 بحسب Nasdaq GlobeNewswire

X4 Pharmaceuticals to Report Third-Quarter 2023 Financial Results and Host a Conference Call and Webcast on November 9, 2023

02 نوفمبر 2023 08:00:01 بحسب Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 نوفمبر 2023 16:05:00 بحسب Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces FDA Acceptance with Priority Review of U.S. NDA for Mavorixafor in WHIM Syndrome

31 أكتوبر 2023 08:00:13 بحسب Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Appointment of Industry Veteran R. Keith Woods to Board of Directors

18 أكتوبر 2023 08:00:01 بحسب Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 أكتوبر 2023 16:05:00 بحسب Nasdaq GlobeNewswire

X4 Pharmaceuticals to Participate in the Cantor Global Healthcare Conference

19 سبتمبر 2023 08:00:00 بحسب Nasdaq GlobeNewswire

X4 Pharmaceuticals to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference

06 سبتمبر 2023 08:00:00 بحسب Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Submission of New Drug Application (NDA) to U.S. FDA for Mavorixafor in WHIM Syndrome

05 سبتمبر 2023 08:00:00 بحسب Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 سبتمبر 2023 16:05:00 بحسب Nasdaq GlobeNewswire

X4 Pharmaceuticals Reports Second-Quarter 2023 Financial Results, Provides Corporate Updates, and Reports Emerging Data from Chronic Neutropenia Clinical Program

10 أغسطس 2023 06:05:00 بحسب Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Industry Veteran Dr. Christophe Arbet-Engels to Join as Chief Medical Officer

08 أغسطس 2023 16:05:00 بحسب Nasdaq GlobeNewswire

X4 Pharmaceuticals Closes $115 Million Loan Facility with Hercules Capital

03 أغسطس 2023 08:00:00 بحسب Nasdaq GlobeNewswire

X4 Pharmaceuticals to Report Second-Quarter 2023 Financial Results and Host a Conference Call and Webcast on August 10, 2023

02 أغسطس 2023 08:01:00 بحسب Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

30 يونيو 2023 16:05:00 بحسب Nasdaq GlobeNewswire

X4 Pharmaceuticals Expected to Join Russell 3000® Index

13 يونيو 2023 08:00:01 بحسب Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 يونيو 2023 16:05:00 بحسب Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Positive Phase 3 Results Showing Mavorixafor Reduced the Rate, Severity, and Duration of Infections vs. Placebo in Participants Diagnosed with WHIM Syndrome

16 مايو 2023 16:01:00 بحسب Nasdaq GlobeNewswire